EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. launches non-US offering of net share settled convertible bonds
Source: EQS
EQS-Ad-hoc: NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN
Ad-hoc announcement pursuant to Art. 17 MAR
Venlo, The Company intends to issue the Bonds in minimum denominations of The Company plans to issue the Bonds with a maturity of 7 years. The Bonds will be issued at par, will bear interest at a rate of 2.125% to 2.625% per annum, payable semi-annually in arrear, and will, unless previously converted, redeemed or repurchased and cancelled, be redeemed at par at maturity. The Company may redeem all, but not some only, of the Bonds outstanding at par plus accrued interest with effect on or after The final terms of the Bonds will be expected to be determined later today, In the event of an exercise of their conversion right, holders of the Bonds will receive a cash amount equivalent to the par value of the Bonds, plus a number of Shares such that the sum of the cash amount and value of Shares delivered is equivalent to the value of the Shares underlying the Bonds, as determined in the terms and conditions. The expected settlement date of the Bonds is QIAGEN intends to use the net proceeds from the issuance of the Bonds for general corporate purposes, including the refinancing of existing indebtedness. In connection with the Offering, QIAGEN will agree not to sell any securities that are substantially similar to the Bonds or its Shares for a lock-up period ending 90 calendar days following the settlement date, subject to certain exceptions and waiver by the joint global coordinators.
Hulsterweg 82 5912 PL Venlo
ISIN: NL0015001WM6
For further information, please contact:
Disclaimer:
The contents of this announcement have been prepared by and are the sole responsibility of QIAGEN and the information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed by any person for any purpose on the information contained in this announcement or its accuracy, fairness or completeness. The distribution of this announcement and the offer and sale of the Bonds in certain jurisdictions may be restricted by law. The Bonds may not be offered to the public in any jurisdiction in circumstances which would require the preparation or registration of any prospectus or offering document relating to the Bonds in such jurisdiction. No action has been taken by QIAGEN or any other party involved in the offering or any of their respective affiliates that would permit an offering of the Bonds or possession or distribution of this announcement or any other offering or publicity material relating to such securities in any jurisdiction where action for that purpose is required. Persons into whose possession this announcement comes are required to inform themselves about and to observe any such restrictions. This announcement is for information purposes only and does not constitute or form a part of an offer to sell or a solicitation of an offer to purchase any security of QIAGEN in Neither this announcement nor any copy of it may be taken, transmitted or distributed, directly or indirectly in or into For readers in the European Economic Area: This communication is only addressed to and directed at persons who are qualified investors as defined in Regulation (EU) 2017/1129 of the For readers in the MiFID II professionals / ECPs-only (all distribution channels) / No PRIIPs KID / No sales to retail investors in the EEA and the Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MIFID II Product Governance Requirements) may otherwise have with respect thereto, the Bonds have been subject to a product approval process which has led to the conclusion that: (i) the target market for the Bonds is eligible counterparties and professional clients only, each as defined in Directive 2014/65/EU (as amended, "MiFID II"); and (ii) all channels for distribution of the Bonds to eligible counterparties and professional clients are appropriate. Any person subsequently offering, selling or recommending the Bonds (a "distributor") should take into consideration the manufacturers' target market assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the Bonds (by either adopting or refining the manufacturers' target market assessment) and determining appropriate distribution channels. The target market assessment is without prejudice to the requirements of any contractual or legal selling restrictions in relation to any offering of the Bonds and/or the underlying shares. For the avoidance of doubt, the target market assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Bonds. The Bonds are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area ("EEA") or End of Inside Information
|
Language: | English |
Company: | |
Hulsterweg 82 | |
5912 PL Venlo | |
Phone: | +31 7735566 - 00 |
Fax: | +31 77 35566-58 |
E-mail: | qiagen@qiagen.com |
Internet: | www.qiagen.com |
ISIN: | NL0015001WM6 |
WKN: | A400D5 |
Indices: | DAX, TecDAX |
Listed: | Regulated Market in |
EQS News ID: | 1980069 |
End of Announcement |
|
1980069 03-Sep-